subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma
Published 5 years ago • 1.6K plays • Length 5:00Download video MP4
Download video MP3
Similar videos
-
5:20
phase 3 study of sc vs iv daratumumab in patients with relapsed or refractory multiple myeloma
-
1:33
subcutaneous daratumumab show benefit in patients with relapsed or refractory multiple myeloma
-
8:36
alnuctamab, a bcma x cd3 t-cell engager, in pts with relapsed/refractory multiple myeloma
-
2:59
daratumumab in combination with carfilzomib and dex in len-refractory patients with rmm
-
6:59
teclistamab in combination with sub-q daratumumab and lenalidomide in myeloma pts: majestec-2
-
11:11
rationale for selinexor treatment in daratumumab-refractory multiple myeloma patients
-
3:48
subcutaneous daratumumab in r/r myeloma: the columba trial
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
3:52
is dara being used in the frontline setting for myeloma patients?
-
7:06
efficacy and safety of elranatamab bcma-cd3 bispecific antibody, in patients with rrmm
-
1:44
trimm-2: talquetamab daratumumab in patients with r/r multiple myeloma
-
6:14
results of iberdomide in combination with dex and daratumumab or bortezomib in patients with rrmm
-
5:31
quality of life in pts with rrmm treated with pomalidamide and dex ± subcutaneous dara: apollo
-
2:22
impact of daratumumab monotherapy on bone parameters in relapsed refractory multiple myeloma pts
-
0:49
dr. martin on subcutaneous administration of daratumumab in multiple myeloma
-
10:57
linker-mm1 study: linvoseltamab (regn5458) in patients with rr multiple myeloma | asco 2023
-
7:02
talquetamab in pts with relapsed/refractory multiple myeloma: phase 1/2 results from monumental-1
-
1:41
dara-vmp prolongs os in pts with transplant-ineligible newly diagnosed multiple myeloma patients
-
9:14
efficacy and safety of elranatamab in pts with relapsed/refractory multiple myeloma: magnetismm-3